Carotid atheroma characterization by carotid echo doppler : study of correlations between carotid and coronary artery atheroma.

Contexte : L'echodoppler carotidien (EDC) est un outil pour définir le risque cardio-vasculaire (RCV) mais peut progresser dans ses indications et dans les paramètres mesurés. Les travaux 1-2-3 étudient les correlations échographiques de l'index de volume de plaque (IVP). Les études 4-5 étudient l’apport de l’EDC dans l'évaluation du RCV des patients avec syndromes coronaires aigus (SCA). Matériels: les études N°1-2-3 ont été réalisées sur 93 patients avec EDC. Les études 4-5 ont été réalisées sur 152 patients avec SCA et EDC systématique. Les analyses sont transversales et longitudinales. Résultats : L'IVP n’est pas corrélé aux paramètres usuels de quantification de l’athérome carotidien. Il est plus sensible que le degré de sténose pour mesurer les changements de la plaque d’athérome. L'EDC chez tous les patients atteints de SCA est peu rentable. Ciblé aux patients âgés et diabétiques, il améliore ses performances. Les plaques carotidiennes 50-70 % ont une valeur pronostique significative. Conclusion : L’EDC est un outil intéressant pour aborder le RCV. Sa meilleure utilisation (quantitative et qualitative) permet de mieux appréhender le RCV.Background: Carotid echo Doppler (EDC) is an interesting tool to define the cardio vascular risk (RCV) of patients. However its performances could be increased with creation of new parameters The studies n°1, 2 and 3 studied the correlations between the plaque volume index (IVP) and the currently used echographic parameters. Studies n° 4 and 5 studied the contribution of EDC for evaluating the RCV in patients with an acute coronary syndrome (ACS). Materials: Studies n°1,2 and 3 were performed on 93 patients with EDC. Studies n° 4 and 5 were performed on 152 patients with an SCA and EDC systematically achieved. Results: IVP was not correlated with the parameters currently used to quantify carotid atheroma. IVP was more sensible than the stenosis degree to detect the changes in carotid atheroma. EDC performed in all patients with an SCA could not be justified. Performed in elderly and diabetic patients, this tool was very useful to detect severe stenosis with an impact on patients’s management. Asymptomatic Carotid narrowing between was found to have a prognostic value. Conclusion: EDC is an interesting tool to understand the RCV. Its better use (quantitative and qualitative) should allow to reduce the CV morbid mortality

Caractérisation échographique de la pathologie carotidienne athéromateuse (étude des corrélations entre la pathologie athéromateuse carotidienne et coronaire.)

Contexte : L'echodoppler carotidien (EDC) est un outil pour définir le risque cardio-vasculaire (RCV) mais peut progresser dans ses indications et dans les paramètres mesurés. Les travaux 1-2-3 étudient les correlations échographiques de l'index de volume de plaque (IVP). Les études 4-5 étudient l apport de l EDC dans l'évaluation du RCV des patients avec syndromes coronaires aigus (SCA). Matériels: les études N1-2-3 ont été réalisées sur 93 patients avec EDC. Les études 4-5 ont été réalisées sur 152 patients avec SCA et EDC systématique. Les analyses sont transversales et longitudinales. Résultats : L'IVP n est pas corrélé aux paramètres usuels de quantification de l athérome carotidien. Il est plus sensible que le degré de sténose pour mesurer les changements de la plaque d athérome. L'EDC chez tous les patients atteints de SCA est peu rentable. Ciblé aux patients âgés et diabétiques, il améliore ses performances. Les plaques carotidiennes 50-70 % ont une valeur pronostique significative. Conclusion : L EDC est un outil intéressant pour aborder le RCV. Sa meilleure utilisation (quantitative et qualitative) permet de mieux appréhender le RCV.Background: Carotid echo Doppler (EDC) is an interesting tool to define the cardio vascular risk (RCV) of patients. However its performances could be increased with creation of new parameters The studies n1, 2 and 3 studied the correlations between the plaque volume index (IVP) and the currently used echographic parameters. Studies n 4 and 5 studied the contribution of EDC for evaluating the RCV in patients with an acute coronary syndrome (ACS). Materials: Studies n1,2 and 3 were performed on 93 patients with EDC. Studies n 4 and 5 were performed on 152 patients with an SCA and EDC systematically achieved. Results: IVP was not correlated with the parameters currently used to quantify carotid atheroma. IVP was more sensible than the stenosis degree to detect the changes in carotid atheroma. EDC performed in all patients with an SCA could not be justified. Performed in elderly and diabetic patients, this tool was very useful to detect severe stenosis with an impact on patients s management. Asymptomatic Carotid narrowing between was found to have a prognostic value. Conclusion: EDC is an interesting tool to understand the RCV. Its better use (quantitative and qualitative) should allow to reduce the CV morbid mortality.TOURS-Bibl.électronique (372610011) / SudocSudocFranceF

Prévalence et modalités de dépistage des sténoses carotidiennes chez les patients hospitalisés pour un syndrome coronaire aigu

TOURS-BU Médecine (372612103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

INFLUENCE DES ANOMALIES DE CONDUCTION SUR LA MECANIQUE CARDIAQUE ET LA TOLERANCE A L'EFFORT DANS LES CARDIOMYOPATHIES DILATEES EN RYTHME SINUSAL

RENNES1-BU Santé (352382103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Different Criteria of Cardiac Resynchronization Therapy and Their Prognostic Value for Worsening Heart Failure or Major Arrhythmic Events in Patients With Idiopathic Dilated Cardiomyopathy

International audienceThere are still controversies about pertinent criteria for cardiac resynchronization therapy (CRT) and prophylactic indications for biventricular cardioverter-defibrillators, particularly in idiopathic dilated cardiomyopathy (IDC). This study compared several criteria for resynchronization therapy in IDC among those of several completed trials. In 201 patients with IDC, the relative risk for (1) death from heart failure (HF) or heart transplantation and (2) sudden death or sustained ventricular tachyarrhythmia were calculated separately according to the inclusion criteria of the Multisite Stimulation in Cardiomyopathy (MUSTIC), InSync, Multicenter InSync Randomized Clinical Evaluation (MIRACLE), Pacing Therapies for Congestive Heart Failure (PATH-CHF), Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION), and CONTAK studies. The percentage of patients meeting the criteria ranged from 6% for those of MUSTIC to 23% for those of CONTAK. In a follow-up of 51 +/- 42 months, 28 patients died (15 from progressive HF, 13 from sudden death), 20 underwent heart transplantation, and 12 had sustained ventricular tachyarrhythmia. Relative risks of worsening HF ranged from 3.14 (95% confidence interval [CI] 1.41 to 6.99, p = 0.005) for the MIRACLE criteria to 4.63 (95% CI 1.76 to 12.2, p = 0.0019) for the MUSTIC criteria. Only the CONTAK criteria were significantly associated with a risk for major arrhythmic events (2.65, 95% CI 1.19 to 5.95, p = 0.018). Arrhythmic events constituted 16% of all cardiac events for the MUSTIC patients, 11% for InSync patients, 31% for PATH-CHF patients, 36% for MIRACLE patients, 38% for COMPANION patients, and 42% for CONTAK patients. In conclusion, in IDC, the less restrictive criteria for CRT were associated with the greatest risk for arrhythmic events. In contrast, patients with the MUSTIC criteria for CRT mainly had a risk for worsening HF and may not benefit from biventricular cardioverter-defibrillators

Revascularization algorithm in acute STEMI should take into account age

International audienc

Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1

International audienceSummary In patients with atrial fibrillation (AF) and an intermediate risk of stroke (CHADS2 score =1), available evidence from clinical trials is inconclusive and the present guidelines for the management of AF indicate that the choice between oral anticoagulant and aspirin in these patients is open. Our goal was to evaluate whether, in patients with AF and only one moderate risk factor for thromboembolism, treatment with an oral anticoagulant is appreciably more beneficial than treatment with an antiplatelet agent. Among 6,517 unselected patients with AF, 1,012 of them (15.5%) had a CHADS2 score of 1 and were liable to treatment with an antiplatelet agent or an anticoagulant. An oral anticoagulant was prescribed for 606 patients (59.9%) and an antiplatelet agent or no antithrombotic treatment for 406 (40.1%). During follow-up (median=793 days, interquartile range=1,332 days), 105 deaths (10.4%) and 19 strokes (1.9%) were recorded. The administration of an anticoagulant was associated with a lower rate of events (relative risk=0.42, 95% confidence interval 0.29–0.60, p<0.0001) than when no anticoagulant was prescribed. Results remained similar after adjustment for age and other confounding factors. In contrast, prescription of an antiplatelet agent was not associated with a lower risk of events. Factors independently associated with an increased risk of events were older age (p<0.0001), concomitant heart failure (p=0.0002), diabetes (p=0.0025), lack of prescription of an anticoagulant (p<0.0001) and permanent AF (p=0.04). Thus, prescription of an anticoagulant is independently associated with a decreased risk of death or stroke among patients with AF and a CHADS2 score =1

Decline in platelet count in patients treated by percutaneous coronary intervention : definition, incidence, prognostic importance, and predictive factors

Aims: We investigated the incidence, predictors, and prognostic impact of a decline in platelet count (DPC) in patients treated by percutaneous coronary intervention (PCI). Methods and results: A total of 10 146 consecutive patients treated by PCI from 2003 to 2006 were included. According to the magnitude of the DPC, the population was divided into four groups: no DPC (<10%), minor DPC (10–24%), moderate DPC (25–49%), and severe DPC (≥50%). The primary haemorrhagic endpoint was a composite of post-procedure surgical repair major bleeding. The primary ischaemic endpoint was 30-day all-cause mortality–non-fatal myocardial infarction. Among the total population, 36% had a DPC <10%, 47.7% had a DPC of 10–24%, 14% had a DPC of 25–49%, and 2.3% had a DPC ≥50%. On multivariate analysis, moderate and severe DPC were independent predictive factors of the ischaemic outcome. Two procedural practices were identified that, if modified, might reduce the incidence of acquired thrombocytopaenia. Both the intraprocedural use of heparin (as opposed to bivalirudin) and of low molecular weight contrast material were independently associated with severe acquired thrombocytopaenia. Conclusion: Moderate and severe DPC are independent predictors of adverse bleeding and ischaemic outcomes in PCI. Adoption of intraprocedural anticoagulant other than heparin and avoidance of a low molecular weight contrast agent could potentially decrease the occurrence of severe acquired thrombocytopaenia.9 page(s